PRMT5 and cancer: In summary, a rationallydesigned mechanism switch was achievedin a series of compounds that selectively inhibit the PRMT5•MTAcomplex relative to the PRMT5•SAM complex and selectively kill MTAP-deleted cancer cells relative to MTAP WT cells.